These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 9617505)

  • 1. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
    Piercey MF
    Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
    Bennett JP; Piercey MF
    J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
    Ling ZD; Robie HC; Tong CW; Carvey PM
    J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
    Seeman P; Ko F; Willeit M; McCormick P; Ginovart N
    Synapse; 2005 Nov; 58(2):122-8. PubMed ID: 16088951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramipexole in the treatment of Parkinson's disease: new developments.
    Möller JC; Oertel WH
    Expert Rev Neurother; 2005 Sep; 5(5):581-6. PubMed ID: 16162081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.
    Piercey MF; Hoffmann WE; Smith MW; Hyslop DK
    Eur J Pharmacol; 1996 Sep; 312(1):35-44. PubMed ID: 8891576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical studies of pramipexole: clinical relevance.
    Hubble JP
    Eur J Neurol; 2000 May; 7 Suppl 1():15-20. PubMed ID: 11054154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
    Künig G; Pogarell O; Möller JC; Delf M; Oertel WH
    Clin Neuropharmacol; 1999; 22(5):301-5. PubMed ID: 10516884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum.
    Piercey MF; Walker EL; Feldpausch DL; Camacho-Ochoa M
    Neurosci Lett; 1996 Nov; 219(2):138-40. PubMed ID: 8971799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
    Aloisi G; Silvano E; Rossi M; Millan MJ; Maggio R
    Neuropharmacology; 2011; 60(2-3):439-45. PubMed ID: 21035472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease.
    Joyce JN; Millan MJ
    Curr Opin Pharmacol; 2007 Feb; 7(1):100-5. PubMed ID: 17174156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.
    Presgraves SP; Borwege S; Millan MJ; Joyce JN
    Exp Neurol; 2004 Nov; 190(1):157-70. PubMed ID: 15473989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
    Depoortère R; Bardin L; Rodrigues M; Abrial E; Aliaga M; Newman-Tancredi A
    Behav Pharmacol; 2009 Jul; 20(4):303-11. PubMed ID: 19584712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonists.
    Williams M; Wright S; Lloyd GK
    Trends Pharmacol Sci; 1997 Sep; 18(9):307-10. PubMed ID: 9345846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.